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Background: Mineralocorticoid receptor antagonists (MRAs) have been shown to be effective in patients with heart
failure or myocardial infarction complicated by a reduced ejection fraction. However, the role of MRAs in patients
with preserved ejection fraction (PEF) remains to be clarified. We aimed to summarize the evidence for the efficacy
of MRAs in patients with either heart failure with PEF (HF-PEF) or myocardial infarction with PEF (MI-PEF).
Methods: We searched PubMed, EMBASE, Cochrane Library, and clinical trials databases for randomized controlled
trials, through June 2014, assessing MRA treatment in HF-PEF or MI-PEF patients. Fourteen randomized controlled
trials (MI-PEF, 5; HF-PEF, 9; n = 6,428 patients) were included.
Results: MRA treatment reduced the risk of hospitalization for heart failure (relative risk, 0.83; 95% confidence
interval [CI], 0.70 to 0.98), improved quality of life (weighted mean difference [WMD], −5.16; 95% CI, −8.03 to −2.30),
left ventricular end-diastolic diameter (standardized mean difference, −0.21; 95% CI, 0.32 to −0.11), and serum
amino-terminal peptide of procollagen type-III level (WMD, −1.50, 95% CI, −1.72 to −1.29) in patients with PEF. In
addition, MRAs reduced E/e'(an echocardiographic estimate of filling pressure for assessment of diastolic function;
WMD, −1.82; 95% CI, −2.23 to −1.42) in HF-PEF patients and E/A ratio (the ratio of early to late diastolic transmitral
flow; WMD, 0.12; 95% CI, 0.10 to 0.14) in MI-PEF patients. However, all-cause mortality was not improved by MRAs in
either HF-PEF (P = 0.90) or MI-PEF (P = 0.27) patients.
Conclusions: MRA treatment in PEF patients led to reduced hospitalization for heart failure, quantifiable
improvements in quality of life and diastolic function, and reversal of cardiac remodeling, but did not provide any
all-cause mortality benefit.
Keywords: Meta-analysis, Mineralocorticoid receptor antagonists, Preserved ejection fraction, Randomized
controlled trialBackground
Approximately half of patients with heart failure (HF)
have normal or only mildly impaired left ventricular ejec-
tion fractions (LVEFs) [1,2]. Patients with this profile,
known as HF with preserved ejection fraction (HF-PEF),
have signs, symptoms, quality of life (QoL), and prognoses
similar to HF patients with a reduced ejection fraction
(HF-REF) [3,4]. Furthermore, patients with acute myocar-
dial infarction (MI) often have preserved ejection fraction* Correspondence: jianpingbin@126.com
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unless otherwise stated.(PEF) [5]. Although many medical therapies benefit HF
patients and post-MI patients with reduced LVEF [6], ef-
fective, evidence-based pharmacologic treatments are not
currently available for PEF patients [7].
Aldeosterone-based activation of mineralocorticoid re-
ceptors has been demonstrated to contribute to the pa-
thogenesis of HF and adverse cardiac remodeling after
MI through multiple mechanisms, mainly including sym-
pathetic activation, promotion of cardiac and vascular
fibrosis, endothelial dysfunction, sodium retention, and
potassium loss [8,9]. Mineralocorticoid receptor antag-
onists (MRAs) may inhibit these deleterious effects [10]his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for PEF patients. MRAs are effective for reducing total
and cardiovascular mortality in patients with HF-REF
(LVEF <35%) and post-MI patients with left ventricular
dysfunction (LVEF <40%) [11-13]. However, whether
they have a role in PEF remains to be clarified.
A recent series of studies assessed the efficacy of
MRAs in HF-PEF patients and in patients with PEF after
MI (MI-PEF) [14-19]. Although some studies failed to
show a significant mortality benefit for MRA use [14,15],
a number demonstrated a range of secondary benefits
such as improved QoL, diastolic function, and cardiac re-
modeling, in response to MRA therapy [16-19]. As pa-
tients with PEF are usually older than HF-REF patients, a
comprehensive evaluation may help provide support for
therapy that improves symptoms and QoL, rather than
mortality. In addition, since diastolic dysfunction and car-
diac remodeling are considered the major underlying
cardiac pathophysiology in HF-PEF and MI-PEF [20],
combining data regarding the impact of MRAs on these
related parameters might elucidate some encouraging
findings. However, data combining the experience from
published randomized controlled trials to evaluate the
effects of MRAs in PEF patients do not exist. Given the
limited evidence concerning MRAs in PEF patients, this
meta-analysis aimed to summarize the available data
from randomized controlled trials (RCTs) to determine
the efficacy and safety of MRAs in PEF (including both
HF-PEF and MI-PEF) patients.Methods
This meta-analysis was performed and reported ac-
cording to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines
(Additional file 1) [21].Literature search
We searched the MEDLINE, EMBASE, Cochrane Library
databases, and clinical trials databases (clinicaltrials.gov,
controlled-trials.com, and clinicaltrialsregister.eu) for ran-
domized controlled trials conducted between January
2000 and June 2014, using the following key words: i)
mineralocorticoid receptor antagonists, aldosterone re-
ceptor antagonist, canrenoate, canrenoate potassium,
canrenone, canrenoic acid, spironolactone, or eplerenone;
ii) preserved left ventricular function, preserved ejection
fraction, heart failure with normal ejection fraction, or dia-
stolic heart failure; and iii) randomized controlled trials.
Our literature search was limited to studies involving hu-
man subjects, reported in English. The list of full search
strategies for EMBASE and MEDLINE is provided in
Additional file 2. The search strategies for other databases
are available on request.Inclusion criteria
We included prospective, RCTs that: i) enrolled adult
PEF patients with LVEFs ≥40% (including post-MI pa-
tients and those with symptomatic or asymptomatic
HF), ii) assigned patients to MRA treatment versus pla-
cebo or control, iii) had at least one of the clinical out-
comes of interest, and iv) had a study duration of at
least 4 months.
Data extraction
Two independent reviewers screened all titles and the
abstracts of all citations; potentially relevant articles were
assessed according to the inclusion criteria. Disagreements
were discussed until a consensus on inclusion/exclusion
was reached. Information on patient characteristics, study
design, quality, intervention strategies, and clinical out-
comes was systematically extracted from each report using
a standardized form. Data regarding safety and adverse
events, including hyperkalemia and gynecomastia, were
also noted. Hyperkalemia was defined as a potassium
level >5.5 mmol/L. We used definitions of renal failure
and gynecomastia as per the primary trial publication.
The quality of the included RCTs was assessed using
the Jadad quality scale [22].
Outcome measures
The clinical outcomes for this meta-analysis were all-
cause mortality and hospitalization due to HF. We also
assessed echocardiographic parameters related to dia-
stolic function, including E/e' (an estimate of filling pres-
sure used to assess diastolic function), E/A (the ratio of
early to late diastolic transmitral flow), E-wave dece-
leration time, and isovolumic relaxation time (IVRT)
andvariables related to left ventricular structure and
function, including LVEF, left ventricular end-diastolic
volume index, left atrial volume index (LAVI), and left
ventricular mass index (LVMI). More importantly, we
also assessed relevant outcomes in terms of serum indi-
cators and functional capacities: B-type natriuretic pep-
tide, amino-terminal peptide of procollagen type-III
(PIIINP), QoL, and 6-min walking distance.
Statistical analysis
For categorical variables, we calculated the relative risk
(RR) and the absolute risk reduction (RD), as well as
the corresponding 95% confidence intervals (CIs) for the
outcome variables of interest, using the DerSimonian and
Laird random effects model. Quantitative outcomes chan-
ging between baseline and follow-up were summarized
and compared between the treatment and control groups
using the weighted mean difference (WMD) and 95% CI,
unless the outcomes used different scales, when the stan-
dardized mean difference (SMD) and 95% CI were used.
The random-effects model using the DerSimonian and
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cause we anticipated heterogeneity between the trials [23].
A priori, we defined significant heterogeneity between tri-
als as an I2 value of >50% [24]. We assessed the evidence
of publication bias using a funnel plot with an Eggers test
[25]. A two-sided Pvalue <0.05 was considered statistically
significant for all analyses.
Predefined subgroup analyses were conducted, a priori,
according to the PEF subtypes (HF-PEF and MI-PEF),
treatment durations (6 to 11 months, and ≥12 months),
and MRA agent used (spironolactone, canrenoate, ore-
plerenone). If a given trial could be split into two or
more separate studies, based on different treatment
time points, the study with the longest follow-up was
included in the meta-analyses. If a given trial could be
split into two MRA groups with different doses, theFigure 1 Flowchart of study search and selection in this meta-analysi
antagonists; RCTs, Randomized controlled trials.group receiving the standard dose was included in the
meta-analyses. Sensitivity analyses were conducted using
sequential omission of a single study from the total stu-
dies and evaluating the influence of each study on the
pooled effect estimates. All analyses were performed
using Stata, version 11.2 (Stata Corp, College Station,
TX, USA).
Results
Figure 1 displays the study selection flow diagram. The
primary search for randomized clinical trials on MRAs
and PEF generated 1,422 potentially relevant articles.
After screening the titles and abstracts of all studies, 121
full-text articles met the general inclusion criteria and
were reviewed for strict inclusion or exclusion criteria.
Finally, 14 RCTs were included [5,14-19,26-32].s. MI, Myocardial infarction; MRAs, Mineralocorticoid receptor
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All trials (Table 1) were parallel arm trials, with a mean
(± SD) duration of 11.75 ± 10.36 (range, 6 to39.6) months.
Of the included trials, nine were conducted in HF-PEF
(n = 4,127) [14,16,26-32] and five (n = 2,301) in MI-PEF
patients [5,15,17-19]. Thus, a total of 6,428 participants
were randomly assigned to receive MRAs (n = 3,249),
placebo (n = 2,861), standard therapy (n = 301), or active
comparator treatment (n = 17). The withdrawal rates were
comparable between the MRA treatment groups (9.86%)
and control groups (10.79%). Spironolactone was the pre-
dominant MRA used (eight trials) [5,14,16,19,27-29,32],
followed by eplerenone (four trials) [15,17,30,31] and can-
renoate (two trials) [18,26]. Placebo controls were used in
all except four trials. Of these four trials, one used active
comparators (ACE inhibitor [26]) and the other three used
standard therapy [5,17,19]. Background medical therapy
was inconsistently reported. The Treatment of Preserved
Cardiac Function Heart Failure with an Aldosterone An-
tagonist (TOPCAT) trial [14] accounted for more than
half of the patients in this meta-analysis. The Jadad scores
of individual trials ranged from 1 to 5 (mean, 3.36 ± 1.34)
and only three trials [16,17,32] had clear allocation con-
cealment (Additional file 3: Table S1). Patient characteris-
tics for the included studies are presented in Additional
file 3: Tables S2 and S3.
Effect of MRAs on clinical outcomes
The combined data from the 14 RCTs did not show a
significant association between MRA treatment and re-
duced all-cause mortality in PEF patients (RD, −0.00;
95% CI, −0.01 to 0.01; P = 0.71; I2 = 0%; Figure 2A, and
RR, 0.90; 95% CI, 0.78 to 1.04; P = 0.17; I2 = 0%; Additional
file 4: Figure S1A). Treatment with MRAs did not sig-
nificantly reduce the incidence of all-cause mortality in
the nine HF-PEF or in the five MI-PEF trials (P = 0.88
and P = 0.60, respectively). When analyzed by drug type,
none of the individual therapies improved outcomes com-
pared with the control group (spironolactone, P = 0.29;
canrenoate, P = 0.18; eplerenone, P = 0.97; Additional
file 4: Figure S1B). None of the individual studies sig-
nificantly influenced the pooled all-cause mortality esti-
mate in the leave-one-out sensitivity analysis (Additional
file 4: Figure S1C); publication bias was not observed
(P = 0.31, Additional file 4: Figure S1D).
Four studies [14,15,31,32] reported the outcomes of
hospitalization due to HF involving 4,551 participants
and 472 events. Overall, MRA treatment was associated
with a reduced risk of hospitalization due to HF (RR,
0.83; 95% CI, 0.70 to 0.98; P = 0.03; I2 = 0%; Figure 2B,
and RD, −0.01; 95% CI, −0.03 to 0.00; P = 0.05; I2 = 0%;
Additional file 4: Figure S2A); a weight of 96.2% came
from the TOPCAT trial. None of the individual studies
influenced the pooled estimate of hospitalization due toHF (Additional file 4: Figure S2B); publication bias was
not observed (P = 0.74; Additional file 4: Figure S2C).
Four studies reported the composite outcomes for deaths
due to cardiovascular causes, aborted cardiac arrest, or
hospitalization due to HF. Overall, MRA treatment did
not significantly reduce the incidence of the composite
outcome (RR, 0.89; 95% CI, 0.79 to 1.01; P = 0.07; I2 = 0%,
Additional file 4: Figure S3A). When analyzed according
to PEF subtype, a significant benefit was not observed for
either HF-PEF (P = 0.18) or MI-PEF (P = 0.14) patients.
Given the marked regional variation in event rates ob-
served in the TOPCAT trial, we performed a separate
pooled analysis, excluding patients randomized into TOP-
CAT trial from Russia and the republic of Georgia. The
results showed that MRA treatment significantly reduced
the incidence of composite outcome of death from cardio-
vascular causes, aborted cardiac arrests, or hospitalizations
due to HF in PEF patients (RR, 0.85; 95% CI, 0.74 to 0.96;
P = 0.01; I2 = 0%; Additional file 4: Figure S3B).
Effect of MRAs on echo indexes of diastolic function
Overall, E/e', reported in 460 patients enrolled in four
RCTs, was significantly improved following MRA treatment
(WMD, −1.82; 95% CI, −2.23 to −1.42; I2 = 0%; Figure 3A),
without evidence of publication bias (P = 0.36). None of
the individual studies significantly influenced the pooled
estimate for E/e' (Additional file 4: Figure S4A). The E/A
ratio was the most common diastolic function variable, re-
ported in 1,535 patients enrolled in 10 RCTs. Using data
from three trials involving MI-PEF patients, MRA treat-
ment significantly improved the E/A ratio (WMD, 0.12;
95% CI, 0.10 to 0.14; Figure 3B). However, the effect esti-
mates for HF-PEF patients did not show improved E/A ra-
tios (P = 0.97; Figure 3B). When analyzed by drug type,
canrenoate treatment was associated with significant im-
provement in the E/A ratio (WMD, 0.13; 95% CI, 0.07 to
0.20; I2 = 29.8%; Additional file 4: Figure S4B). Treatment
duration did not influence the pooled estimate (Additional
file 4: Figure S4C).
For deceleration time, significance was attained among
both HF-PEF (WMD, −14.35; 95% CI, −28.65 to 0.06;
I2 = 75.8%; Figure 3C) and MI-PEF (WMD, 6.70; 95%
CI, 3.45 to 9.95; I2 = 0%; Figure 3C) patients. Among
the independent trials, overall estimates did not reach
significance for IVRT (P = 0.66; Figure 3D).
Effect of MRAs on indexes of cardiac structure and
function
With all trials included in the meta-analysis, improve-
ment in LVEF (WMD, 2.22; 95% CI, 1.35 to 3.10; I2 = 0%;
Figure 4A) and left ventricular end diastolic diameter
(LVEDD) (SMD, −0.21; 95% CI, 0.32 to −0.11; I2 = 0%;
Figure 4B) was apparent. No publication bias was evi-
dent (P = 0.94 and P = 0.61, respectively; Additional file 4:
Table 1 Characteristics of included studies




Grand I (2002) [26] USA HF-PEF and HBP LVEF >50%; BP >140/90 mmHg; LV
diastolic dysfunction; normal renal function
Canrenone:50 17 (NR) 6
ACEI 17 (NR)
Mottram (2004) [27] Australia HF-PEF and HBP LVEF >50%; NYHA II; E/A <1 Spironolactone:25 15 (NR) 6
Placebo 15 (NR)
Roongsritong (2005) [28] USA Elderly with HF-PEF LVEF >45%; Age:60–85 years; mild diastolic
dysfunction
Spironolactone:25 15 (1) 4
Placebo 15 (1)
Orea-Tejeda (2007) [29] Mexico HF-PEF LVEF >40%; shortening fraction = 28% Spironolactone:25–50 14 (NR) 13.79
Standard therapy 14 (NR)
Mak (2009) [30] Ireland HF-PEF LVEF >45%; NYHA IV; BNP ≥100 pg/mL;
diastolic dysfunction
Eplerenone:25 24 (0) 12
Standard therapy 20 (2)
RAAM-PEF trial (2011) [31] USA HF-PEF LVEF >50%; NYHA II or III; BNP ≥100 pg/mL Eplerenone:25 (titrated to 50) 23 (0) 7
Placebo 23 (2)
Aldo-DHF trial (2013) [16] Germany and Austria HFPEF LVEF >50%; NYHA II or III; Diastolic
dysfunction grade≥ I
Spironolactone:25 213 (9) 11.6
Placebo 209 (13)
Kurrelmeyer (2014) [32] USA Elderly women
with HF-PEF
LVEF >50%; NYHA II or III; E/e' > 15; BNP
>62 pg/mL
Spironolactone:25 24 (0) 6
Placebo 24 (0)
TOPCAT trial (2014) [14] Americas, Russia,
and Georgia
HF-PEF LVEF >45%; control blood pressure; BNP
≥100 pg/mL or NT-proBNP ≥360 pg/mL,
diastolic dysfunction (grade≥ I)
Spironolactone:15–45 1722 (160) 39.6
Placebo 1723 (151)
DiPasquale (2005) [18] Italy MI-PEF LVEF >40%; ST >1 mm in the peripheral
leads and/or >2 mm in precordial leads
Canrenoate:25 341 (33) 6
placebo 346 (30)
Kayrak (2010) [19] Turkey MI-PEF LVEF >40%; successfully revascularized
patients with AMI
Spironolactone:25 71 (16) 6
Standard therapy 71 (16)
Kampourides (2012) [17] Greece MI-PEF LVEF >40%; AMI 1 day to 7 days Eplerenone:25 210 (9) 30
Standard therapy 140 (38)
Vatankulu (2013) [5] Turkey MI-PEF LVEF >40%; successfully revascularized
patients with AMI
Spironolactone:25 54 (NR) 6
Standard therapy 56 (NR)
REMINDER trial (2014) [15] European countries MI-PEF LVEF >40%; successfully revascularized
patients with AMI
Eplerenone: 25 (titrated to 50) 506 (82) 10.5
Placebo 506 (79)
ACEI, Angiotensin-converting enzyme inhibitor; AMI, Myocardial infarction; BNP, B-type natriuretic peptide; E/A ratio, the ratio of early to late diastolic transmitral flow; E/e', an echocardiographic estimate of filling
pressure for assessment of diastolic function; HBP, High blood pressure; HF-PEF, Heart failure with preserved systolic function; LVEF, Left ventricular ejection fraction; MI-PEF, Myocardial infarction with preserved systolic













Figure 2 Pooled analyses of all-cause mortality and hospitalization for heart failure in the mineralocorticoid receptor antagonist group
versus controls. (A) All-cause hospitalization; (B) Hospitalization due to heart failure. CI, Confidence interval; MRA, Mineralocorticoid receptor
antagonist; RD, Absolute risk reduction; RR, Relative risk.
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according to PEF subtype, found that the improvement
in LVEF remained significant in both the HF-PEF and
MI-PEF groups (Figure 4B). Subgroup analysis by treat-
ment duration found that the MRA benefit on LVEDD
was significant over 6 months, but not over 12 months
(Additional file 4: Figure S5C).
For LAVI, the overall effect estimates did not de-
monstrate any significant benefit of MRA treatment
(WMD, −0.11; 95% CI, −0.27 to 0.06; I2 = 0%; P = 0.26;
Figure 4C). Similarly, MRA treatment was not associ-
ated with significant LVMI improvement (WMD, −0.12;
95% CI, −0.28 to 0.05; I2 = 0%; P = 0.22; Figure 4D). Fur-
ther subgroup analyses failed to demonstrate signifi-
cance for LAVI and LVMI (Figure 4D).Effect of MRAs on functional capacity and serum indicators
The pooled analyses of QoL and 6-min walk distance are
shown in Figure 5A and B, respectively. When the QoL
was measured using the Kansas City Cardiomyopathy
Questionnaire clinical summary score (KCCQ CSS), MRA
treatment was associated with a significant improvement
in QoL in HF-PEF patients (WMD, −5.16; 95% CI, −8.03
to −2.30; I2 = 0%; P < 0.0001; Figure 5A). However, the
Minnesota Living with Heart Failure questionnaire QoL
measurements did not improve significantly. In the three
HF-PEF trials that reported 6-min walk distance, a non-
significant change was seen (WMD, −7.97; 95% CI, −16.51
to 0.57; I2 = 0%; P = 0.07; Figure 5B).
Pooling the results of all qualified trials found a sig-
nificant serum PIIINP level reduction (WMD, −1.50;
Figure 3 Forest plots for effect of MRAs on echo indexes of diastolic function. (A) Changes in E/e'; (B) E/A ratio changes; (C) DT changes;
(D) IVRT changes. CI, Confidence interval; DT, E-wave deceleration time; E/A ratio, the ratio of early to late diastolic transmitral flow; E/e', an
echocardiographic estimate of filling pressure for assessment of diastolic function; IVRT, Isovolumic relaxation time; MRA, Mineralocorticoid
receptor antagonist; WMD, Weighted mean difference.
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cant publication bias (P = 0.01). As for B-type natri-
uretic peptide (or amino terminal-proB-type natriuretic
peptide), the pooled analysis did not show a significant re-
duction in the MRA group (WMD, −4.83; 95% CI, −46.12
to 36.45; I2 = 52.8%; P = 0.82; Figure 5D).
Safety and adverse events
Hyperkalemia was reported in all but one trial [28]. Over
a mean follow-up period of 12.19 months, the MRA group
showed a higher rate of hyperkalemia (>5.5 mmol/L) with
12.15% of the MRA groups and 6.16% of the control
groups reporting hyperkalemia (P < 0.001). The TOPCAT
trial, which had the highest reported rates of hyperkale-
mia, involved spironolactone treatment (15 to 45 mg).
Renal failure, using definitions from within each trial, oc-
curred in 1.91% of MRA patients and in 0.37% of control
patients. Gynecomastia was reported in seven studies
[5,14,16,19,26,29,31] involving MRA (2.81%) and control
(0.30%) patients.Discussion
In this meta-analysis of RCTs involving 6,248 patients,
the effects of MRAs on patients with either MI-PEF or
HF-PEF were evaluated. MRA treatment reduced the
risk of hospitalization due to HF, improved QoL, reduced
the E/e' or E/A ratio, increased LVEF, and reduced LVEDD
and PIIINP levels in PEF patients. However, significant all-
cause mortality benefits were not seen.
As patients with HF-PEF are usually older than HF-REF
patients, hospitalization due to HF is increasing and
represents a major burden in these patients [1,33], and
emphasizes the growing need for effective, evidence-based
therapies. However, previous pharmacological interven-
tions, such as angiotensin-converting enzyme inhibitors
[34], angiotensin receptor blockers [35], and beta-blockers
[36], have failed to show a significant reduction in hospi-
talizations due to HF. This meta-analysis provides import-
ant insights into the potential efficacy of MRA treatment
for reducing the rate of hospitalizations due to HF in
PEF patients, without increasing mortality. Reducing
Figure 4 Forest plots for effect of MRAs on indexes of cardiac structure and function. (A) LVEF changes; (B) LVEDD changes; (C) LAVI
changes; (D) LVMI changes. CI, Confidence interval; LAVI, Left atrial volume index; LVEDD, Left ventricular end-diastolic diameter; LVEF, Left
ventricular ejection fraction; LVMI, Left ventricular mass index; SMD, Standardized mean difference; MRA, Mineralocorticoid receptor antagonist;
WMD, Weighted mean difference.
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costs and improve patient QoL. Additionally, significant
MRA treatment benefits on composite outcome of death
from cardiovascular causes, aborted cardiac arrests, or
hospitalizations were observed after excluding patients re-
cruited from Russia and the Republic of Georgia into the
TOPCAT trial. HF-PEF patients from these jurisdictions,
in that trial [14], had extremely low placebo event rates,
incompatible with those in prior HF-PEF studies [35,37].
The separate meta-analysis, excluding this population,
might provide a more realistic insight into the effective-
ness of MRAs in HF-PEF patients. Furthermore, we dem-
onstrated that MRA treatment was associated with a
significant improvement in QoL, measured by the KCCQ
CCS. The KCCQ CCS has been reported to be a valid and
reliable measure of health status and QoL in HF-PEF pa-
tients [38]. Since the HF-PEF patients were elderly and
typically demonstrated multiple comorbidities that might
affect their mobility, it is not surprising that MRA treat-
ment improved KCCQ CCS scores in these patients, butnot exercise tolerance [39]. Therefore, MRA treatment
could be an option in PEF patients to improve their QoL.
Another encouraging finding from this meta-analysis
was that MRAs improved both diastolic and systolic
functions in PEF patients. Left ventricular diastolic dys-
function is the major underlying cardiac pathophysiology
of PEF patients, and worse diastolic dysfunction has
been associated with an increased risk of mortality [40].
However, earlier pharmacotherapy did not achieve a sig-
nificant improvement in diastolic function in HF-PEF
patients [7,41,42]. The present meta-analysis supports
the potential clinical value of MRAs for improving dia-
stolic function in PEF patients. We also found that MRA
treatment significantly reduced the E/e' in HF-PEF pa-
tients and the E/A ratio in MI-PEF patients. Interestingly,
MRAs were not associated with a significant reduction
in the E/A ratio in HF-PEF patients. This may be be-
cause this ratio is rather complicated and cannot pro-
vide unequivocal evidence of diastolic dysfunction in
HF-PEF [43], whereas E/e' was demonstrated to be the
Figure 5 Forest plots for effect of mineralocorticoid receptor antagonists on serum indicators and functional capacity. (A) Quality of life
changes; (B) 6-MWD changes; (C) PIIINP changes; (D) BNP changes. 6-MWD, 6-minute walk distance; BNP, B-type natriuretic peptide; CI, Confidence
interval; KCCQ CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; PIIINP, Serum amino-terminal peptide of procollagen type-III;
MLWHF, Minnesota Living with Heart Failure questionnaire; MRA, Mineralocorticoid receptor antagonist; WMD, Weighted mean difference.
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in HF-PEF [43]. Our meta-analysis also found that
MRA administration led to increased LVEF in PEF pa-
tients. A previous meta-analysis demonstrated that MRAs
improved systolic function in HF-REF [44]. Thus, the
present meta-analysis shows that the beneficial effect of
MRAs on systolic function also extends to PEF patients.
Although the favorable impact of MRAs on cardiac re-
modeling is well known in patients with HF and reduced
LVEF [44], the effect of MRAs in patients with preserved
systolic function remained uncertain. This meta-analysis
demonstrated that MRA administration could reverse
cardiac remodeling in patients with preserved systolic
function through a reduction of LVEDD and PIIINP levels.
A subgroup analysis of LVEDD, based on treatment dur-
ation, found that the reduction became insignificant as the
duration increased. This finding is consistent with a previ-
ous meta-analysis focusing on the effect of MRAs on car-
diac structure in patients with left ventricular dysfunction
[44]. As PIIINP level has been proposed as an indicator ofcardiac remodeling and poor clinical prognosis [45], a re-
duction in serum PIIINP level might reflect the beneficial
effects of MRAs on cardiac remodeling.
The benefits of MRAs on PEF patients are mainly at-
tributed to the improvement of endothelial function and
cardiac remodeling, as well as the decrease of myocardial
fibrosis. Experimental evidence indicates that aldosterone-
induced mineralocorticoid receptor activation provides an
important unifying mechanism for many of the pathologic
alterations of HF-PEF and MI-PEF [46,47]. The MRAs,
through direct inhibition of aldosterone, were demon-
strated to reduce myocardial fibrosis, improve vascular
compliance and endothelial function, decrease inflam-
mation and oxidative stress, and reduce the release of
norepinephrine [48]. These changes likely account for
the diastolic function improvements seen on echocardi-
ography and the reduction in collagen markers such as
serum PIIINP level. MRA treatment was also associated
with an increased risk of hyperkalemia and elevated serum
creatinine levels. Our findings underscore the importance
Chen et al. BMC Medicine  (2015) 13:10 Page 10 of 12of monitoring electrolyte disorders and serum markers
of kidney function during MRA treatment in clinical
practice.
Several issues should be considered in the interpret-
ation of our results. First, this meta-analysis was limited
by the discrepancies in PEF diagnostic criteria employed
in the clinical trials. The diagnosis of HF-PEF is still
challenging because various criteria have been proposed
to define patients with “diastolic HF” [49]. The included
RCTs had differing ejection fraction cut-off criteria (range,
40 to 50%) and challenges in diagnostic criteria for PEF,
and may have resulted in a heterogeneous population.
Nevertheless, patients with an ejection fraction of 40 to
50%, defined as borderline and intermediate PEF in the
American College of Cardiology Foundation/American
Heart Association guidelines [49], were characteristic-
ally and prognostically similar to those with an ejection
fraction ≥ 50% [50]. Therefore, our meta-analysis does
suggest a potential MRA treatment benefit for PEF pa-
tients. Second, some publication bias might exist in this
meta-analysis, as we only included articles published in
English. However, our statistical tests reported a low
probability of publication bias in the pooling analysis.
Third, different follow-up durations in the included tri-
als might have produced heterogeneity, which limited
the interpretation of pooled effect estimates. Finally, as
the reported totals for all-cause mortality and hospitali-
zations due to HF were low, the assessment of the effect
on clinical outcomes in PEF patients was of limited power.
Despite the majority of evidence regarding clinical out-
comes coming from the recently reported TOPCAT trial
[14], the findings of previous trials appear consistent.Conclusions
This meta-analysis of RCTs in PEF patients demons-
trated that MRA treatment may exert beneficial effects,
including reduced hospitalizations due to HF, improved
QoL and diastolic function, and cardiac remodeling re-
versal, without an effect on all-cause mortality. The sig-
nificant increase in hyperkalemia and serum creatinine
level associated with MRA treatment underscores the
need for careful monitoring of electrolyte disorders and
serum markers of kidney function in clinical practice.
Further large-scale RCTs are needed to confirm the clini-
cal indications for this medication class.Additional files
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